Community Research and Development Information Service - CORDIS


Final Report - ADAMANT (Antibody derivatives as molecular agents for neoplastic targeting)

Project ID: 201342
Funded under: FP7-HEALTH


This is the final report of the ADAMANT project, in which researchers have developed and implemented state-of-the-art methodologies for the identification and validation of proteins which are preferentially expressed in the tumour neo-vasculature and stroma. The study is divided into four milestones, explored in the objectives chapter. Later, the potential impact and dissemination activities are described.

The project led to the development of novel biopharmaceutical agents which could eradicate tumours that are not cured by conventional pharmacological interventions. Some of the newly developed products are now being studied in clinical trials. The project has led to an improved understanding of the molecular composition of the tumour neo-vasculature and of the tumour stroma. The project allowed the development of novel anti-cancer products, stimulating industrial activities in Europe and leading to the implementation of novel therapeutic concepts and of new clinical trials.

Download application/zip (1453261)

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top